Welcome to our dedicated page for NEVRO news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on NEVRO stock.
Nevro Corp. (NYSE: NVRO), headquartered in Redwood City, California, is a pioneering global medical device company dedicated to improving the lives of patients suffering from chronic pain through innovative products. The company's flagship product, the Senza® Spinal Cord Stimulation (SCS) System, is an evidence-based neuromodulation platform designed to treat chronic pain. This system features Nevro's proprietary HF10 therapy, which is known for its high-frequency, paresthesia-free stimulation, approved by the FDA in 2015, and commercially available in the U.S., Europe, and Australia.
Nevro's comprehensive product portfolio includes the HFX™ Spinal Cord Stimulation (SCS) Platform, comprising Senza®, Senza II®, Senza Omnia®, and HFX iQ™ systems. These devices offer patients a non-pharmacologic solution to manage chronic pain and painful diabetic neuropathy, providing sustainable pain relief and improved quality of life. The HFX platform also includes support services such as HFX Coach™ for patients and HFX Cloud™ for physicians, ensuring enhanced patient management and outcomes.
In November 2023, Nevro expanded its portfolio by acquiring Vyrsa Technologies, a company specializing in minimally invasive sacroiliac joint (SI joint) fusion devices. This strategic move allows Nevro to address a broader range of chronic pain conditions, particularly chronic SI joint pain. Vyrsa's innovative implants and proprietary technologies complement Nevro's existing offerings, positioning the company for significant market penetration and growth.
Financially, Nevro has shown resilience and adaptability. For the full year of 2023, the company reported worldwide revenues of $425.2 million, reflecting a 5% increase from the previous year. Despite challenges, Nevro's solid performance is attributed to its continuous focus on commercial execution, market penetration, and profitability. The company recently secured a $200 million term loan credit facility to refinance its 2025 convertible notes and ensure long-term financial stability.
Nevro's commitment to innovation is further evidenced by the recent FDA clearance of its sacroiliac joint fusion device, Nevro1, which is designed to enhance the stability and fusion of the SI joint using proprietary transfixing technology and bone-growth enhancing materials. This product, alongside the existing portfolio, reinforces Nevro's leadership in the chronic pain management market.
The company also maintains strong strategic partnerships and collaborations, ensuring that its solutions reach a wide patient base. Recent policy updates, such as the expansion of coverage for spinal cord stimulation for painful diabetic neuropathy by Carelon Healthcare, have significantly increased access to Nevro's therapies, benefiting millions of patients across the United States.
Going forward, Nevro remains dedicated to its mission of delivering life-changing solutions for chronic pain, continuously advancing its product offerings, and maintaining its commitment to improving patient outcomes globally.
Nevro Corp. (NVRO) reported its Q3 financial results for 2021, revealing worldwide revenue of $93.2 million, down 14% year-over-year. Net loss from operations reached $46.4 million, influenced heavily by a $20 million patent litigation judgment. The gross profit decreased to $64.6 million, with a margin of 69.3%. The company provided Q4 revenue guidance of $94 million to $98 million, indicating an 11% to 14% decline compared to the previous year. The quarter's performance was impacted by COVID, affecting patient procedures, but the FDA approval of 10 kHz SCS Therapy for PDN offers a potential growth avenue.
Nevro Corp. (NYSE: NVRO) announced a jury verdict finding it in infringement of two Boston Scientific patents regarding spinal cord stimulation leads, resulting in a $20 million award to Boston Scientific. Despite this outcome, Nevro asserts that there are no commercial implications for current or future products. The company plans to appeal the decision, emphasizing that the lawsuit is a retaliatory action from Boston Scientific stemming from a prior lawsuit filed by Nevro. Nevro continues to maintain its position in the market as the exclusive provider of its patented 10 kHz Therapy.
Nevro Corp. (NYSE: NVRO), a leading medical device company specializing in chronic pain solutions, announced that CEO D. Keith Grossman will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The presentation will be accessible starting November 22, 2021, at 10:00 am ET. Investors can find a webcast and archived recording on Nevro's website. Nevro is known for its innovative Senza spinal cord stimulation system, which offers non-pharmacologic treatment options for chronic pain, aiming to enhance the quality of life for patients.
Nevro Corp. (NYSE: NVRO) has announced that it will report its third quarter financial results for the period ending September 30, 2021, after market close on November 8, 2021. A conference call will be held on the same day at 1:30 PM PT to discuss these results. Investors can participate by dialing in or accessing a live webcast available on Nevro's website. Nevro specializes in innovative medical devices for chronic pain treatment, notably through its proprietary 10 kHz Therapy that has shown significant efficacy in reducing opioids usage among patients.
Nevro Corp. (NYSE: NVRO) announced the appointment of Sri Kosaraju to its Board of Directors, effective August 31, 2021. Kosaraju brings extensive experience in life sciences and medical technology, having served as CEO of Inscripta and former President of Penumbra. His vast background in healthcare positions him to support Nevro's growth and product development. Nevro is known for its innovative spinal cord stimulation systems aimed at improving chronic pain treatment, with its proprietary 10 kHz Therapy showing significant efficacy in clinical studies.
Nevro Corp. (NYSE: NVRO), a leader in medical devices aimed at chronic pain treatment, announced that its Chairman and CEO, D. Keith Grossman, will present at the Baird 2021 Global Healthcare Conference on September 15, 2021, at 10:50 AM ET. A live webcast and archived recording will be accessible on Nevro's website. The company specializes in innovative spinal cord stimulation (SCS) systems, including the Senza® platform, delivering proprietary 10 kHz Therapy.
On August 25, 2021, Supermoon Capital launched a $36 million venture fund focused on early-stage startups innovating in the sleep sector. This fund is the first of its kind, targeting the growing 'Night Market™,' which is valued at $488 billion. Co-founded by Pat Connolly and Michael Masterson, the fund aims to address significant sleep issues affecting 75% of Americans. Investments include six startups, such as Clair Labs and Endel, aimed at improving sleep health through science-backed innovations.
Nevro Corp. (NYSE: NVRO), a leading medical device company, will be represented by Chairman, CEO, and President D. Keith Grossman at the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 11:45 AM Eastern Time. Investors can access a live webcast and an archived recording of the presentation on Nevro's website. The company specializes in innovative solutions for chronic pain treatment, including its proprietary Senza spinal cord stimulation systems.
Nevro Corp. (NYSE: NVRO), a medical device leader in chronic pain solutions, announced that CEO D. Keith Grossman will present at the Wells Fargo Virtual Healthcare Conference on September 10, 2021, at 8:00 am ET. A live webcast of the presentation will be available on Nevro's investor website. Nevro specializes in innovative spinal cord stimulation systems, including the Senza, Senza II, and Senza Omnia, delivering proprietary 10 kHz Therapy. Investors are encouraged to monitor the company's website for updates and important information.
Nevro Corp. (NVRO) reported Q2 2021 revenues of $102.3 million, an 81% increase from the previous year. Despite a net loss of $15.8 million, non-GAAP adjusted EBITDA improved to $3.0 million. The FDA approved its 10 kHz spinal cord stimulation therapy for painful diabetic neuropathy, enhancing its market position. However, Q3 revenue guidance is set at $90-$93 million, reflecting a decrease of 14%-17% year-over-year. The company is cautious due to ongoing COVID-19 impacts on patient procedures and future growth prospects.
FAQ
What is the current stock price of NEVRO (NVRO)?
What is the market cap of NEVRO (NVRO)?
What is Nevro Corp's core business?
What is the Senza SCS system?
What recent acquisition has Nevro Corp made?
What financial performance did Nevro Corp report for 2023?
What are some of Nevro's key products?
What support services does Nevro provide?
What is HF10 therapy?
How has Nevro expanded access to its therapies?
What are Nevro's strategic goals?
What new product did Nevro recently receive FDA clearance for?
